Ullrich G Mueller-Lisse1,2, Larissa Marwitz3, Amanda Tufman4,5, Rudolf M Huber4,5, Hanna A Zimmermann3, Annemarie Walterham3, Stefan Wirth3, Marco Paolini3,5. 1. Department of Radiology, Klinikum der Universität München, LMU - University of Munich, Ziemssenstrasse 1, 80336, Munich, Germany. ullrich.mueller-lisse@med.uni-muenchen.de. 2. Member of the German Centre for Lung Research (DZL) - CPC-M, Munich, Germany. ullrich.mueller-lisse@med.uni-muenchen.de. 3. Department of Radiology, Klinikum der Universität München, LMU - University of Munich, Ziemssenstrasse 1, 80336, Munich, Germany. 4. Department of Pneumology, Klinikum der Universität München, LMU - University of Munich, Ziemssenstrasse 1, 80336, Munich, Germany. 5. Member of the German Centre for Lung Research (DZL) - CPC-M, Munich, Germany.
Abstract
PURPOSE: Mediastinal, hilar, and peripheral pulmonary lymphadenopathy is a hallmark sign of different benign and malignant diseases of the chest. Contrast-enhanced (CE) chest CT is a test frequently applied to examine thoracic lymph node zones. We attempted to find out whether mediastinal, hilar, and peripheral lymph nodes delineate equally in CE chest CT with reduced dose (CE-LDCT, about 1 mSv) when compared with accepted standard CE chest CT (CE-SDCT). MATERIALS AND METHODS: In this ethics committee-approved, mono-institutional, retrospective (20 months) matched case-control study, two independent, blinded observers compared measurable lymph node delineation (yes-no) in six different International Association for the Study of Lung Cancer (IASLC) zones (upper mediastinal, aortopulmonary, subcarinal, lower mediastinal, hilar, peripheral) between 62 CE-LDCT cases and 124 CE-SDCT controls (respective tube charge, 100, 120 KVp, computed tomography dose index, 1.66 ± 0.51, 5.36 ± 2.24 mGy, automatic exposure control-modulated 64-row multi-detector chest CT with iterative image reconstruction). Individual matching for gender (53% female), age (53 ± 19 years), body height, weight, anterior-posterior and transverse diameters of chest and lung ruled out pre-test confounders. Lymph node size (cut-off value, 1 cm) was a potential post-test confounder. Two-tailed T test and Chi-square test were significant for p < 0.05. RESULTS: Measurable lymph nodes delineated equally in cases (261/372 IASLC zones, 70%; 280/372, 75%) and controls (528/744, 71%; 519/744, 70%; no significant differences, power 90%). One observer delineated significantly more peripheral zone lymph nodes in cases (35/62) than in controls (43/124); there were no significant differences otherwise. Lymph node size did not differ significantly; effective dose was 1.0 ± 0.3 mSv in cases and 3.4 ± 1.5 mSv in controls. CONCLUSION: CE-LDCT with about 1 mSv demonstrated equal delineation of thoracic lymph nodes when compared with accepted standard CE-SDCT.
PURPOSE: Mediastinal, hilar, and peripheral pulmonary lymphadenopathy is a hallmark sign of different benign and malignant diseases of the chest. Contrast-enhanced (CE) chest CT is a test frequently applied to examine thoracic lymph node zones. We attempted to find out whether mediastinal, hilar, and peripheral lymph nodes delineate equally in CE chest CT with reduced dose (CE-LDCT, about 1 mSv) when compared with accepted standard CE chest CT (CE-SDCT). MATERIALS AND METHODS: In this ethics committee-approved, mono-institutional, retrospective (20 months) matched case-control study, two independent, blinded observers compared measurable lymph node delineation (yes-no) in six different International Association for the Study of Lung Cancer (IASLC) zones (upper mediastinal, aortopulmonary, subcarinal, lower mediastinal, hilar, peripheral) between 62 CE-LDCT cases and 124 CE-SDCT controls (respective tube charge, 100, 120 KVp, computed tomography dose index, 1.66 ± 0.51, 5.36 ± 2.24 mGy, automatic exposure control-modulated 64-row multi-detector chest CT with iterative image reconstruction). Individual matching for gender (53% female), age (53 ± 19 years), body height, weight, anterior-posterior and transverse diameters of chest and lung ruled out pre-test confounders. Lymph node size (cut-off value, 1 cm) was a potential post-test confounder. Two-tailed T test and Chi-square test were significant for p < 0.05. RESULTS: Measurable lymph nodes delineated equally in cases (261/372 IASLC zones, 70%; 280/372, 75%) and controls (528/744, 71%; 519/744, 70%; no significant differences, power 90%). One observer delineated significantly more peripheral zone lymph nodes in cases (35/62) than in controls (43/124); there were no significant differences otherwise. Lymph node size did not differ significantly; effective dose was 1.0 ± 0.3 mSv in cases and 3.4 ± 1.5 mSv in controls. CONCLUSION:CE-LDCT with about 1 mSv demonstrated equal delineation of thoracic lymph nodes when compared with accepted standard CE-SDCT.
Authors: Tracy A Jaffe; Terry T Yoshizumi; Greta Toncheva; Colin Anderson-Evans; Carolyn Lowry; Chad M Miller; Rendon C Nelson; Carl E Ravin Journal: AJR Am J Roentgenol Date: 2009-10 Impact factor: 3.959
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: PLoS Med Date: 2007-10-16 Impact factor: 11.069
Authors: Mario Buty; Ziyue Xu; Aaron Wu; Mingchen Gao; Chelyse Nelson; Georgios Z Papadakis; Uygar Teomete; Haydar Celik; Baris Turkbey; Peter Choyke; Daniel J Mollura; Ulas Bagci; Les R Folio Journal: Tomography Date: 2017-06
Authors: Alexander Gäble; Julian Hebebrand; Marco Armbruster; Fabian Mück; Maria Berndt; Bernhard Kumle; Ulrich Fink; Stefan Wirth Journal: Radiologe Date: 2020-03 Impact factor: 0.635